Calliditas Therapeutics AB (STO:CALTX), a speciality pharmaceutical company, announced on Thursday the appointment of Dr Krassimir Mitchev, PhD, as chief medical officer (CMO), effective 1 December 2019.
Currently, Mitchev is head of Medical Affairs at Calliditas, having joined the company in March 2019. He is an MD and PhD certified in internal and pulmonary medicine, with broad and extensive academic and pharmaceutical industry career experience, including at GSK and UCB. Prior to his current position, he was medical head for haemophilia at SOBI.
Mitchev takes over the role from Dr Jens Kristensen, who has decided to step down for personal reasons. According to the company, Dr Kristensen will remain a key member of the medical team of the company.
Dr Kristensen joined Calliditas in 2016 and has been instrumental in the design of the ongoing phase 3 study (NefIgArd) and the overall clinical development of Calliditas' leading compound Nefecon.
Calliditas Therapeutics is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialisation efforts.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic